353 results about "RA - Rheumatoid arthritis" patented technology

The invention discloses a preparation method of a periploca forrestii schltr extract as well as the product and application of the periploca forrestii schltr extract. The preparation method comprises the following steps: adding 60%-80% ethanol the weight of which is 8-12 times that of the medicinal material periploca forrestii schltr into the taken periploca forrestii schltr; carrying out reflux extraction for 1-3 times, wherein each reflux extraction lasts for 1-3 hours; filtering, mixing filtrates and concentrating until the relative density of the mixed filtrate is 1.2-1.5; adding water the volume is the same as that of the mixed filtrate; and refrigerating and standing for 12-48 hours, taking supernate, recovering ethanol and drying so as to obtain the extract. In the method, the ethanol extraction and water precipitation process is adopted to extract the medicinal material periploca forrestii schltr, and the parameters of the ethanol extraction process and the water precipitation process are optimized respectively. The obtained extract mainly contains flavonoid and triterpene compounds. Tests prove that the extract has obvious therapeutical effects on primary and secondary inflammatory reaction of AA rats and has good effects in the aspects of inflammation resistance, detumescence and relief of arthritis injuries of AA rats. Thus, the extract can be applied to the preparation of medicines for rheumatoid arthritis.

The invention belongs to the technical field of biological medicine, and particularly relates to application of diindolymethane and the derivant thereof in rheumatoid arthritis and preparation of novel aqueous solution preparation of diindolymethane and the derivant thereof. The diindolymethane and the derivant thereof can effectively improve the level of interferon - Gamma in vitro and in vivo and can regulate the immunity of the organism, thereby stopping the happening and development of diseases and reducing the injury caused by the diseases. In addition, the intermediary mainly involved in the water solution preparation of the product is cyclodextrin. The water solution preparation of the product can effectively improve the water solubility, and is convenient for use. The application of the water solution preparation of the product is not limited only within the application on treatment of rheumatoid arthritis, but also includes the application of diindolymethane and the derivant thereof in treatment of other diseases, such as tumor and androgen and estrogen related diseases.

The invention develops a simplified method for the in-vitro isolation and expansion of umbilical mesenchymal stem cells (MSCs) and confirms that the MSCs obtained by the method have the effects of immunoregulation and inflammation inhibition in the treatment of rheumatoid arthritis.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol / L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion / anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL / lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent / necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

The invention relates to a Chinese medicinal extract for treating urarthritis, and the Chinese medicinal extract is characterized by being prepared from the following raw material drugs: Illicium henryi root bark, Illicium henryi root, Illicium henryi stem leaves, anisetree bark, Illicium jiadifengpi or albizia julibrissin, wherein the content of total flavonoid in the extract is between 20 and 80 percent. The invention also provides a preparation method and application of the Chinese medicinal extract, as well as a preparation method and application of quercetin. The invention has the advantages that: pharmacological tests prove that the extract mainly prepared from illicium plant has remarkable prevention and treatment effects on acute urarthritis, does not have toxic or side effect, and can be used for preparing medicaments for preventing and treating urarthritis, and rheumatic or rheumatoid arthritis; new application of the quercetin in urarthritis treatment is discovered; according to the preparation method provided by the invention, toxic components are removed, active components are concentrated and remained, the application curative effect and safety are improved, thereby facilitating the safe application in medical industry and related industries.

Disclosed are nutritional compositions for treating rheumatic diseases. The nutritional compositions contain a fat source containing at least one of: 1) at least one omega-3 long chain polyunsaturated fatty acid and 2) at least one omega-6 long chain polyunsaturated fatty acid; a carbohydrate source; a protein source; and at least one of a Boswellia extract and a Phlebodium extract. Also disclosed are methods of treating rheumatic diseases and symptoms thereof, involving administering to a subject an effective amount of the aforementioned nutritional composition.

The invention discloses a traditional Chinese medicine for treating rheumatoid arthritis, so as to solve the problems of long course of treatment and high side effect caused by treatment of rheumatoid arthritis with western medicine. The medicine comprises astragalus, radix aconiti preparata, Notopterygium, radix angelicae pubescentis, mulberry branch, kadsura pepper stem, bark of himalayan coralbean, cinnamon, herba epimedii, rhizoma curculiginis, winy angelica root, elecampane, frankincense, myrrh, fourstamen stephania root, centipede, whole scorpion and dry liquorice. The composition is used for treatment of rheumatoid arthritis according to dialectic analysis on the rheumatoid arthritis, and has the characteristics of good curative effect, short course of treatment, low toxic and side effect, and being easy to spread, economic and practical.

The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and / or monitoring of treatment regimens.

The invention relates to a composite detection antigen and application thereof, in particular to a composite rheumatoid arthritis detection antigen and application thereof. The detection antigen is acombined antigen of citrullinated protein and carbamylated protein, a kit composed of the detection antigen can detect multiple rheumatoid arthritis autoantibodies at a time, overcomes the disadvantages that single autoantibody detection has inadequate sensitivity and specificity and one-by-one detection of multiple autoantibodies is tedious in operation, and greatly improves the detection efficiency and result judgment accuracy, moreover, the kit provided by the invention also can be used for clinical examination of rheumatoid arthritis and post-treatment curative effect assessment, thus having broad market prospects and huge economic benefits.

The invention discloses a drug composite with analgesia and anti-inflammatory functions and a preparation method thereof. The drug composite comprises two raw material drugs--aconitum sinomontanum andlamiophlomis rotate and the preparation method comprises the following steps: preparing extract by extracting the raw material drugs with water or alcohol, concentrating, drying and other processes,combining extract, and adding common auxiliary material to prepare various common formulations. Experiments show that by jointly utilizing aconitum sinomontanum and lamiophlomis rotata, the dosage ofaconitum sinomontanum can be reduced, the analgesia effect is not reduced; and in anti-inflammatory experiments, aconitum sinomontanum and lamiophlomis rotata are jointly utilized, thereby increasingsingle drug effect and also having synergistic effect. Therefore, the drug composite of the invention has the analgesia and anti-inflammatory functions, is in particular suitable for pains caused by rheumatoid arthritis and malignant tumor, and has better clinical and market prospects.

The invention relates to a preparation and applications of a paeonol controlled-release preparation in the technical field of the medicine. The paeonol controlled-release preparation refers to a group of controlled-release and long-time effective preparations which contain the microspheres and gel matrix tablets used for preparing tablets or capsules, and thermosensitive in situ gel for external use, wherein the specifications of the prepared paeonol controlled-release preparation are 60mg and 120mg; under special conditions, the accumulative release rate at 2h is less than 20% of the labeled amount, the accumulative release rate at 6h is 40-60% of the labeled amount and the accumulative release rate at 12h is more than 80% of the labeled amount respectively; and the paeonol controlled-release preparation can be used to cure rheumatoid arthritis. By using the thermosensitive in situ gel for external use, the preparation residence time of the affected part can be significantly prolonged.

The invention discloses a warm compression thermal therapy liquid for treating rheumatoid arthritis, postpartum rheumatism, scapulohumeral periarthritis, lumbar muscle degeneration, sciatica, lumbar vertebra pain, cervical vertebra pain, hemiplegia and stroke. The warm compression thermal therapy liquid is mainly prepared from double-teeth pubescent angelica root, wild ginger, himalayan teasel root, dandelion, longhairy antenoron herb, fortune's drynaria rhizome, Chinese taxillus twig, astragalus, cortex eucommiae, scorpio, red paeony root, white paeony root, orientvine, prepared rehmannia rhizome, achyranthis bidentatae, large-leaved gentian and red-rooted salvia root according to a certain weight proportion. A preparation method of the warm compression thermal therapy liquid comprises the following steps of: preparing the selected Chinese medicines, extracting, purifying and smashing with a smasher; and applying according to three kinds of methods. The warm compression thermal therapy liquid has the effects of clearing and activating the channels and collaterals, regulating tendons and qi, dispelling cold and drawing poison out, can be used for quickly improving microcirculation and enhancing the immunologic function and temperature resistance of an organism, is applied to treatment of a plurality of incurable miscellaneous diseases such as rheumatoid arthritis, scapulohumeral periarthritis, postpartum rheumatism, sciatica, cervical vertebra lumbar vertebra pain, hemiplegia and stroke and the like, and has quick response and a high curative rate.

The present invention relates to a rheumatoid arthritis autoantibody conjugated antigen and applications thereof. The present invention discloses a novel detection antigen of rheumatoid arthritis antibody, wherein particularly the detection antigen can be used as the RA diagnosis and early diagnosis indicator, and is superior to the clinically developed detections of CCP, CRP, IgG-RF, IgM-RF and the like, such that the detection antigen can be used as the valuable reference indicator for clinical early treatment or prevention of RA, and can further be used as the RA pathogenesis development indicator.

The invention relates to the field of medical science and particularly verifies the existence of a circulating immune complex of peroxide reductase IV, which can be used as a diagnosis marker of rheumatoid arthritis. A capturing agent can be used as a diagnosis reagent of the rheumatoid arthritis. The invention further introduces a diagnosis kit for detecting the content of the circulating immune complex of the peroxide reductase IV of claims; a solid-phase carrier of the diagnosis kit is covered by the capturing agent of the circulating immune complex; the diagnosis kit further comprises a detection reagent which is combined with the capturing agent and can be quantitative. The invention verifies the existence of the circulating immune complex of the peroxide reductase IV for the first time; the invention discloses a content detection method of the circulating immune complex of the peroxide reductase IV, which can accurately detect the content of the circulating immune complex in blood serum of a patient and is good in repeatability; the diagnosis capability of the circulating immune complex of the peroxide reductase IV in the rheumatoid arthritis is higher than that of a RF (Rheumatoid Factor) and anti-CCP (anti-Cyclic Citrullinated Peptide); the circulating immune complex of the peroxide reductase IV can also be used as the diagnosis marker of other diseases and is high in distinction degree.

The invention provides an RANKL-TNF (Receptor Activator of Nuclear Factor Kappa-B Ligand-Tumour Necrosis Factor) sample region fusion protein, and in particular relates to a fusion protein of an RANKL-TNF sample region protein and a Th2 cell epiposition segment with broad host range property. An experiment shows that an antibody produced by an RANKL-TNF sample region fusion protein immune mouse has the effect of combining RANKL with TNF-alpha, can be used for treating diseases such as rheumatoid arthritis and the like and can play effects of antagonistic bone destruction and inflammation inhibition. The RANKL-TNF sample region fusion protein disclosed by the invention can be used as a therapeutic vaccine and provides a new therapeutic approach and thinking for the diseases such as rheumatoid arthritis and the like. According to the invention, the RANKL-TNF sample region fusion protein is expressed in vitro, and therefore the method has the advantages of high expression yield, strong controllability and relatively low production cost;, and the product has good immunogenicity and is easy to realize mass production.

The invention discloses a medicament for treating rheumatoid arthritis and a preparation method thereof. The medicament is mainly prepared from processed semen strychni, black ant, scorpion, centipede, tripterygium wilfordii, processed radix aconiti, asarum, angelica, ginseng, pseudo-ginseng, chuanxiong rhizome, gastrodia tuber, wooly datchmanspipe herb and honey according to certain proportions by weight. The medicament can be prepared into any one of common oral preparations and can also be prepared into externally applied ointment. The medicament disclosed by the invention has the functions of relieving pain, diminishing inflammation, resisting bacteria, promoting blood circulation, dispersing pathogenic wind, activating collaterals, tonifying the kidney, invigorating the spleen, strengthening the liver, nourishing the stomach and expelling toxins. Thus, the medicament has high effect taking speed and high cure rate when used for treating rheumatoid arthritis.

The invention relates to a traditional Chinese medicine composition for improving joint gall of rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine comprises the following raw materials: shinyleaf pricklyash root, kadsura longepedunculata, cortex acanthopanacis, tinospora sinensis merr, clematis chinensis, cissus pteroclada hayata, sargentodoxa cuneata and Chinese starjasmine stem, and is applied to joint gall caused by wind, cold, wet, phlegm and blood stasis obstruction of meridians and collaterals. The effective constituents of the traditional Chinese medicine composition provided by the invention are the following raw materials: shinyleaf pricklyash root, kadsura longepedunculata, cortex acanthopanacis, tinospora sinensis merr, clematis chinensis, cissus pteroclada hayata, sargentodoxa cuneata and Chinese starjasmine stem. The traditional Chinese medicine composition has a remarkable curative effect on the aspect of improving joint gall of the rheumatoid arthritis, and the effect is superior to that of the prior art.

The invention relates to a traditional Chinese medicine and a preparation method thereof, in particular to an external use drug for treating rheumatoid arthritis and a preparation method thereof. The external use drug comprises, by weight, of 8-12 parts of cassia twig, 18-22 parts of drynaria rhizome, 18-22 parts of radix rehmanniae, 18-22 parts of rehmannia glutinosa, 18-22 parts of herbaceous peony red root, 28-32 parts of lycopodium clavatum, 10-14 parts of silkworm larva, 8-12 parts of dried body of ground beetle, 8-10 parts of ephedra, 8-10 parts of qiang radix angelicae pubescentis, 8-10 parts of radices sileris and 16-20 parts of radix achyranthis bidentatae. All constituents are made into fine powder to be filled in a medicine bag in a shape of a double-layer glove or double-layer sock. When the external use drug is used, the vinegar is sprayed on the surface of the medicine bag which is placed in a microwave oven to heat 2 minutes, a patient lime with a glove or sock made of pure cotton is sleeved in the medicine bag, the medicine bag can be repeatedly heated, and a patient wears the drug glove or sock for 30-40 minutes each time. The external use drug for treating the rheumatoid arthritis organically bonds various constituents, gives full play to pharmacodynamic effects on the various constituents, absorbs and permeates through skin, has effects on human bodies, is slow in pharmacodynamic effects, can release stably, avoids inconvenience brought by oral medicine, can be easily accepted by the patient and is good in pharmacodynamic effects.

The invention discloses an analgesic bone rheumatoid plaster. The analgesic bone rheumatoid plaster has the functions of relaxing tendons, activating blood circulation, removing blood stasis, dispelling pathogenic wind, dispelling cold, removing dampness, stimulating the menstrual flow, activating collaterals, invigorating bone, relieving pain, resolving hard mass, and the like. The indications comprise bumps, fall injuries, pain on wounds, intercostal neuralgia, lumbar sprain, chest pain, pain in neck, shoulder, waist and lower extremities, rheumatism, rheumatoid arthritis, bone hyperplasia, bone spur, gout, bone fractures, neuropathic pain, and the like, and the efficacy is remarkable. The analgesic bone rheumatoid plaster is characterized in that the plaster can be directly pasted without heating when in application, and the paste oil can not be flowed anywhere and only leave a light mark, thereby not affecting the sanitation and not generating a wound surface on the skin by long-term application.

The invention provides fusion protein of a human interleukin receptor C (IL-17RC). The fusion protein contains a key region where the human IL-17RC is bonded with interleukin 17A(IL-17A) and interleukin 17F(IL-17F)and a human IgG1 Fc segment. The IL-17RC-hFc fusion protein provided by the invention has the capacity of binding the IL-17A and the IL-17F, can inhibit release of inflammatory cytokines and expression of RANKL molecules irritated by the IL-17A and the IL-17F, can be used for treating IL-17 associated autoimmune diseases such as rheumatoid arthritis and the like, and exerts the effects of inhibiting inflammation and antagonizing bone destruction. The IL-17RC-hFc fusion protein can serve as a therapeutic bait receptor and provides a new therapeutic approach and thought for diseases such as rheumatoid arthritis and the like. The IL-17RC-hFc fusion protein is subjected to prokaryotic expression in vitro; and the method is high in expression quantity, high in controllability, relatively low in production cost and easy in large-scale production.

The invention relates to a plaster for treating hyperosteogeny, rheumatism, rheumatoid arthritis and arthritis, which is mainly prepared from the following active pharmaceutical ingredients: long-noded pit viper, cassia twig, raw szechuan aconite, heracleum hemsleyanum michaux, eucommia, radix clematidis, spatholobus stem, club moss, american lopseed, semen momordicae, raw nux vomica, Ningpo yam rhizome, radix sileris, eucommia and the like. The plaster has the advantages of scientific formula and obvious curative effect. Under the synergistic actions of the traditional Chinese medicines, the plaster can perform the functions of expelling wind and clearing away cold, activating blood circulation to dissipate blood stasis, promoting the subsidence of swelling, alleviating pain, nourishing the bone and relaxing tendons, and can promote tissue regeneration, strengthen the body and smooth the meridians, so that the hyperosteogeny is gradually softened, atrophied and healed. Therefore, the plaster has good curative effect on hyperosteogeny, rheumatism, rheumatoid arthritis and arthritis. Clinical application for more than 8 years proves that the plaster has treated 23897 patients with cervical vertebra hyperplasia, knee joint hyperplasia, rheumatism, rheumatoid arthritis, traumatic injury, sprains, lumbar sprain, acute chest pain, stiff neck, strains and lumbar muscle strain, wherein 22056 patients are cured; and thus, the total cure rate is 92.4%.

The present invention provides HAb18G / CD147 function epitone amino acid sequence as shown in the <400>1 or the <400>2 sequence in the sequence list and with serial monoantibody function and the application of the said functional epitone area in preparing medicine for treating tumor recurrence, tumor metastasis, rheumatoid arthritis and osteoarthritis. The found HAb18G / CD147 function area may be used as the targeting molecule in designing, screening and synthesizing its antagonist to block the function of effect cell in inducing and secreting matrix metal protainase, to reduce the degradation of tumor tissue interstitium, joint cartilage erosion and nascent vascularization and to treat tumor recurrence, tumor metastasis, rheumatoid arthritis and osteoarthritis. Therefore, the discovery of the functional epitone has application foreground in developing new medicines.

The invention discloses a traditional Chinese medicine, in particular a traditional Chinese medicine composition for treating rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine composition for treating rheumatoid arthritis is characterized by comprising the following components: aconitum wardii, grass monkshood, Pinellia ternata, rhizoma arisaematis, nux vomica, hindu hatura flower, pseudo-ginseng, dragon's blood, ligusticum wallichii, turmeric, safflower carthamus, corydalis tuber, root of common peony, vinegary armadillo, radix angelica, vinegary frankincense, vinegary myrrh, ginger, camphor and plum blossom borneol. The traditional Chinese medicine is specially used for treating rheumatoid arthritis and a plurality of medicines are matched properly to improve the curative effect by means of inter-synergism or resistance so as to meet the treating requirement of complex condition. The traditional Chinese medicine reduces the adverse reaction, has rapid effect of external treatment, is convenient for external use, safe and reliable and has good treating or symptom relieving effect for rheumatoid arthritis and cervicodynia, omalgia, lumbago and skelalgia. Totally 660 patients are treated and total effective rate reaches 96%.

The invention relates to the field of chemical medicines and concretely relates to a 1-(pyrimidine-4-yl)-3-aminopiperdine derivative and its preparation method and use. The invention provides the 1-(pyrimidine-4-yl)-3-aminopiperdine derivative. The 1-(pyrimidine-4-yl)-3-aminopiperdine derivative has a structure shown in the formula IV. The invention also provides a preparation method and a use of the 1-(pyrimidine-4-yl)-3-aminopiperdine derivative. The 1-(pyrimidine-4-yl)-3-aminopiperdine derivative can selectively inhibit JAK3 and provide a novel choice for treating JAK3-related diseases such as rheumatoid arthritis, asthma, chronic obstructive pulmonary diseases and tumors.

The invention discloses a fusion protein of a single-chain antibody of a human anti-complement C3d molecule and a complement inhibitor CD59. The antibody has excellent antigen binding activity. Biological distribution experiments prove that the fusion protein provided by the invention can be rapidly and highly aggregated at an arthritis part after entering a rheumatoid arthritis mouse model, and has an excellent anti-adhesion / anti-inflammation targeting inhibition effect. In treatment of MRL / lpr lupus erythematosus mice, the fusion protein provided by the invention can obviously improve the survival rate of the mice, and symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis, crescent / necrosis and the like of a treatment group are obviously improved, so that the fusion protein provided by the invention has an excellent application prospect in preparation of medicaments for treating autoimmune diseases.

The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that the activity of CD99, an adhesion molecule known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. Inhibition of the activity of CD99 is predicted to alleviate the symptoms of rheumatoid arthritis.

A Chinese medicine for treating rheumatic and rheumatoid arthiritides is prepared from 32 Chinese-medicinal materials including vomiting nut, scorpion, white atractylodes rhizome, borneol, etc. Its preparing process is also disclosed.

The invention relates to the medical field, and in particular relates to superoxide reductase IV used in the preparation of a rheumatoid arthritis diagnostic agent, an application of the superoxide reductase IV in the preparation of the rheumatoid arthritis diagnostic agent and an application of the superoxide reductase IV in the preparation of a rheumatoid arthritis specific antigen. The superoxide reductase IV has high specificity and sensitivity and is particularly suitable for the application of the early diagnosis agent. The superoxide reductase IV also provides a new idea for the preparation of the rheumatoid arthritis vaccine.

The invention discloses traditional Chinese medicine capsules for treating rheumatoid arthritis and a preparation method thereof. The traditional Chinese medicine capsules are prepared from traditional Chinese medicines including hot rhizoma cibotii, zaocys dhumnades, obscured homalomena rhizome, periploca forrestii schltr, caulis sinomenii, panax pseudoginseng, rhizoma curcumae longae, radix paeoniae alba, liquorice and microcrystalline cellulose. The traditional Chinese medicine capsules disclosed by the invention are exact in curative effect, safe and reliable, convenient to take, quick in drug release, economical and practical in price and convenient to carry, thereby bringing more medication choices to the patients.

To solve the problem of an obvious side effect existing in the traditional Tripterygium Hypoglaucum Hutch root tablet, the invention provides a bi-layer extended release tablet which can reduce medicine peak plasma concentration. A Tripterygium Hypoglaucum Hutch root extract is any one extract of the whole Tripterygium Hypoglaucum Hutch root, Tripterygium Hypoglaucum Hutch root bark, or Tripterygium Hypoglaucum Hutch root core with the bark removed. The Tripterygium Hypoglaucum Hutch extract bi-layer extended release tablet has the characteristics of little untoward effect, and is convenient and safe to use. At the same time, a medicine-time curve is stable, the plasma concentration has small fluctuations, and the half life is prolonged. The Tripterygium Hypoglaucum Hutch root extract extended release bi-layer tablet using the root core with the bark removed has good therapeutic effects on asthma, lupus erythematosus, nephritis, and rheumatoid arthritis.